Cargando…

Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan

BACKGROUND: In Japan, combination therapy with high doses of antipsychotic drugs is common, but as a consequence, many patients with schizophrenia report extrapyramidal and autonomic nervous system side effects. To resolve this, we proposed a method of safety correction of high dose antipsychotic po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukegawa, Tsuruhei, Inagaki, Ataru, Yamanouchi, Yoshio, Inada, Toshiya, Yoshio, Takashi, Yoshimura, Reiji, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234191/ https://www.ncbi.nlm.nih.gov/pubmed/24708857 http://dx.doi.org/10.1186/1471-244X-14-103

Ejemplares similares

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Response to Dr. Okumura
por: Yamanouchi, Yoshio, et al.
Publicado: (2017)

National database study on the use of long‐acting antipsychotic injections and hospital readmission proportions in patients with schizophrenia in Japan
por: Usuki, Masato, et al.
Publicado: (2020)

Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2013)

Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)
por: Mandarelli, Gabriele, et al.
Publicado: (2022)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval
por: Barbui, Corrado, et al.
Publicado: (2016)

Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
por: Kaikoushi, Katerina, et al.
Publicado: (2021)

Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
por: Iwata, Nakao, et al.
Publicado: (2020)

Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
por: Hatano, Masakazu, et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao, Kei, et al.
Publicado: (2013)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Analysis of the trends of polypharmacy and high‐dose prescriptions in Japan
por: Shinfuku, Naotaka
Publicado: (2021)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Prescriptions of Antipsychotics in Younger and Older Geriatric Patients with Polypharmacy, Their Safety, and the Impact of a Pharmaceutical-Medical Dialogue on Antipsychotic Use
por: Gebauer, Eva-Maria, et al.
Publicado: (2022)

Polypharmacy in multimorbid older adults: protocol for a systematic review
por: Sirois, Caroline, et al.
Publicado: (2017)

Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study
por: Ayani, Nobutaka, et al.
Publicado: (2021)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

The cost of schizophrenia in Japan
por: Sado, Mitsuhiro, et al.
Publicado: (2013)

Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence
por: Kishi, Taro, et al.
Publicado: (2011)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
por: Yoshimura, Reiji, et al.
Publicado: (2019)

The impact of COVID-19 on inpatient wards at psychiatric hospitals in Japan
por: Usuda, Kentaro, et al.
Publicado: (2021)

Exploring polypharmacy with artificial intelligence: data analysis protocol
por: Sirois, Caroline, et al.
Publicado: (2021)

No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients
por: Yoshimura, Reiji, et al.
Publicado: (2012)

Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
por: Fisher, Maxine D, et al.
Publicado: (2014)

Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?
por: Lin, Shih-Ku
Publicado: (2019)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients
por: Lassen, Stine, et al.
Publicado: (2023)

Cost of anxiety disorders in Japan in 2008: a prevalence-based approach
por: Sado, Mitsuhiro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cp93gkp0mr12po4d411j41rdfi